Friday, January 08, 2021 8:14:48 PM
Chuckles,
I am profoundly disappointed. I thought for certain the revelation that Cytodyn does not list their payments for leronlimab manufacturing meant that there is a nefarious plot at hand. I started with Keytruda and Humira, but eventually looked more broadly.
I was unable to find any payments for mAb manufacturing listed in the SEC filings from Roche, Johnson & Johnson, Merck, Novartis, AbbVie or Amgen.
Geez, thought I. This must be some kind of scam. Perhaps Samsung and the other major mAb manufacturers are in some weird money laundering or state sanctioned effort to subvert the global biologics market. South Koreans and Samsung pulling a fast one!
Man, what a short opportunity! I could be the short king (is that title taken already? I’ll fight for it!!)
On top of being supremely rich by divining this incredible scam, I should get a Pulitzer for publicizing this.
Maybe even a Noble, err Nobel, in economics just because I figured this out.
Now, NOW!! you tell me that this is common practice?
I guess I’ll just have to go back to burger flipping. Short (Shorts?) lived dream.
I am profoundly disappointed. I thought for certain the revelation that Cytodyn does not list their payments for leronlimab manufacturing meant that there is a nefarious plot at hand. I started with Keytruda and Humira, but eventually looked more broadly.
I was unable to find any payments for mAb manufacturing listed in the SEC filings from Roche, Johnson & Johnson, Merck, Novartis, AbbVie or Amgen.
Geez, thought I. This must be some kind of scam. Perhaps Samsung and the other major mAb manufacturers are in some weird money laundering or state sanctioned effort to subvert the global biologics market. South Koreans and Samsung pulling a fast one!
Man, what a short opportunity! I could be the short king (is that title taken already? I’ll fight for it!!)
On top of being supremely rich by divining this incredible scam, I should get a Pulitzer for publicizing this.
Maybe even a Noble, err Nobel, in economics just because I figured this out.
Now, NOW!! you tell me that this is common practice?
I guess I’ll just have to go back to burger flipping. Short (Shorts?) lived dream.
Recent CYDY News
- Form EFFECT - Notice of Effectiveness • Edgar (US Regulatory) • 05/21/2026 04:15:12 AM
- Form 424B3 - Prospectus [Rule 424(b)(3)] • Edgar (US Regulatory) • 05/20/2026 09:08:39 PM
- CytoDyn to Present at the LD Micro Invitational XVI • GlobeNewswire Inc. • 05/15/2026 12:30:00 PM
- CNS Drug Delivery Breakthroughs Unlock Significant Biotech Market Opportunities • InvestorsHub NewsWire • 05/11/2026 01:00:00 PM
- CNS Drug Delivery Breakthroughs Unlock Significant Biotech Market Opportunities • GlobeNewswire Inc. • 05/11/2026 12:30:00 PM
- Form 8-K - Current report • Edgar (US Regulatory) • 04/30/2026 08:32:50 PM
- CytoDyn Announces First Patient Dosed in Expanded Access Program for Leronlimab in Triple-Negative Breast Cancer • GlobeNewswire Inc. • 04/27/2026 12:30:00 PM
- CytoDyn to Host Investor Webcast • GlobeNewswire Inc. • 04/23/2026 12:30:00 PM
- Form S-1 - General form for registration of securities under the Securities Act of 1933 • Edgar (US Regulatory) • 04/22/2026 09:21:50 PM
- CytoDyn Presents New Leronlimab Data in Metastatic Colorectal Cancer at AACR Annual Meeting 2026 • GlobeNewswire Inc. • 04/22/2026 12:30:00 PM
- CytoDyn Completes Enrollment in Phase 2 Metastatic Colorectal Cancer Study • GlobeNewswire Inc. • 04/21/2026 08:10:00 PM
- CytoDyn Presents New Leronlimab Data in Metastatic Triple-Negative Breast Cancer at AACR Annual Meeting 2026 • GlobeNewswire Inc. • 04/20/2026 12:30:00 PM
- CytoDyn to Present at the AACR Annual Meeting 2026 • GlobeNewswire Inc. • 04/14/2026 12:30:00 PM
- Form 424B3 - Prospectus [Rule 424(b)(3)] • Edgar (US Regulatory) • 04/08/2026 09:15:18 PM
- Form 10-Q - Quarterly report [Sections 13 or 15(d)] • Edgar (US Regulatory) • 04/08/2026 12:30:28 PM
- Form 424B3 - Prospectus [Rule 424(b)(3)] • Edgar (US Regulatory) • 03/25/2026 09:16:10 PM
- Form 4 - Statement of changes in beneficial ownership of securities • Edgar (US Regulatory) • 03/24/2026 09:24:23 PM
- Form 4 - Statement of changes in beneficial ownership of securities • Edgar (US Regulatory) • 03/24/2026 09:23:14 PM
- Form 4 - Statement of changes in beneficial ownership of securities • Edgar (US Regulatory) • 03/24/2026 09:22:42 PM
- Form 4 - Statement of changes in beneficial ownership of securities • Edgar (US Regulatory) • 03/24/2026 09:21:33 PM
- Form 4 - Statement of changes in beneficial ownership of securities • Edgar (US Regulatory) • 03/24/2026 09:20:57 PM
- Form 4 - Statement of changes in beneficial ownership of securities • Edgar (US Regulatory) • 03/24/2026 09:20:20 PM
- Form 8-K - Current report • Edgar (US Regulatory) • 03/24/2026 09:15:24 PM
- CytoDyn Presents at AACR Special Conference in Cancer Research: Brain Cancer • GlobeNewswire Inc. • 03/24/2026 12:30:00 PM
- Form 424B3 - Prospectus [Rule 424(b)(3)] • Edgar (US Regulatory) • 03/09/2026 09:15:18 PM
